Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

By afschroeder • June 25, 2025

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. Oncologist. 2025 Jun 4;30(6):oyaf134. doi: 10.1093/oncolo/oyaf134. PMID: 40549044.

Tags: breast cancer, Denosumab, Endocrinology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

Mdivi-1 regulates mitochondrial fission and function via the CaMK2/Drp1 pathway in amyotrophic lateral sclerosis

Shai Y, Alam M, Dong X, Zhang Y, Hu Y, He Z, Feng J, Chen Y, Zhou Z, Jiang H. Mdivi-1 regulates mitochondrial fission and[...]

Carbohydrate Counting in the Real World: Mealtime Insulin Dosing Behaviors and Smartphone App Use in Adults with Type 1 Diabetes

Everett EM, Shaw E, Escobar B, Cheng D, Tiu R, Lopez R, Menjivar Cruz J, Rivas Deras A, Polan D, Wisk LE, Moin T. Carbohydrate[...]

Exposure to per-and polyfluoroalkyl substances and early-onset cancers

van Gerwen M, Monaghan M, Boni A, Florentino Puello M, Petrick LM, Leung AM. Exposure to per-and polyfluoroalkyl substances and early-onset cancers. Carcinogenesis. 2026 Jul[...]